Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.

Also called NCT02175121

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 172 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02175121
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02175121. Randomized; double masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-03 (actual). Results posted on 2016-06-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type II
Intervention (Drug)
Placebo
Intervention (Drug)
PF-06291874
Intervention (Drug)
PF-06291874
Intervention (Drug)
PF-06291874
Intervention (Drug)
PF-06291874
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02175121
Content hash
4ef294ef0037da739b04b6fcbcb929beba664fd70efb032187da01b28a1ebd56